HIV Researchers’ “Cautionary Tale” for COVID-19 Vaccines

A volunteer participates in South Africa's first human clinical trial for a COVID-19 vaccine. June 28, 2020.  Image: Felix Dlangamandla/Beeld/Gallo Images/Getty
Image credit
A volunteer participates in South Africa's first human clinical trial for a COVID-19 vaccine. June 28, 2020. Image: Felix Dlangamandla/Beeld/Gallo Images/Getty

The researchers behind an ill-fated HIV vaccine have published a letter in The Lancet with their concerns that some COVID-19 vaccine candidates “could increase susceptibility to HIV,” Science reports.
 
Why? Like the HIV vaccine candidate, several COVID-19 vaccine candidates now in clinical trials use “adenovirus 5” as their vector. In a disastrous trial that had once been the best hope for an HIV vaccine, uncircumcised male participants who’d been naturally infected with Ad5 before receiving the vaccine were found to be more vulnerable to HIV.
 
This “cautionary tale” is particularly urgent as some Ad5-based COVID-19 vaccines may soon be tested in countries with a high HIV burden such as South Africa.
 
More Vaccine News: As the pivotal decisions about COVID-19 vaccines draw nearer, a gathering of “nerdy virologists” is set to be the most-watched meeting of an influential US FDA advisory committee ever, POLITICO reports
 
Tune in to the Center for Biologics Evaluation and Research’s (CBER), Vaccines and Related Biological Products Advisory Committee (VRBPAC)  meeting on Thursday.

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top